EUCTR2011-005040-10-IT进行中（未招募）1 期
A phase I/II, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO045 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis).
- •Ambulant boys aged at least 5 years on the day of first dosing able to walk for at least 230 meters in the 6 minute walking distance (6MWD) at the first screening visit and also at the baseline visit. In addition, 2 of the 3 pre-treatment 6MWD tests (screen 1, screen 2, baseline) must be within ± 30 meters of each other prior to first PRO045 administration.
- •Adequate quality for biopsy (confirmed with MRI) of the lateral head of the gastrocnemius muscle. An alternative muscle may be considered for biopsy but only following discussion between the Principal Investigator and the Prosensa Medical Monitor.
- •Life expectancy of at least 3 years after inclusion in the study.
- •Glucocorticosteroid use which is stable for at least 3 months prior to first PRO045 administration. Subjects must have been receiving glucocorticosteroids for at least 6 months prior to the first PRO045 administration.
- •Willing and able to adhere to the study visit schedule and other protocol requirements.
- •Written informed consent signed (by parent(s)/legal guardian and/or the subject, according to the local regulations).
- •In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 45
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Known presence of dystrophin in =5% of fibres in a pre-study diagnostic muscle biopsy (i.e. historic muscle biopsy taken prior to written informed consent for this study).
- •Current or history of liver disease or impairment.
- •Current or history of renal disease or impairment.
- •At least two aPTT above ULN within the last month.
- •Screening platelet count below the lower limit of normal (LLN).
- •Acute illness within 4 weeks prior to first dose of PRO045 which may interfere with the study assessments.
- •Severe mental retardation or behavioural problems which, in the opinion of the investigator, prohibit participation in this study.
- •Severe cardiomyopathy which in the opinion of the investigator prohibits participation in this study. If a subject has a left ventricular ejection fraction <45% at screening, the investigator should discuss inclusion of the subject with the Medical Monitor.
- •Expected need for daytime mechanical ventilation within the next year.
- •Use of anticoagulants, antithrombotics or antiplatelet agents.
- •Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of the screening for the study.
- •Use of nutritional or herbal supplements which, in the opinion of the investigator, may influence muscle performance, within1 month of the study
- •Use of any other investigational product or participation in another trial with an investigational product, within 6 months prior to the start of the screening for the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, open-label study to assess the efficacy and tolerability of ZD6474 ZACTIMA 100 mg monotherapy in subjects with locally advanced or metastatic hereditary medullary thyroid cancer - NDocally advanced or metastatic hereditary medullary thyroid cancerMedDRA version: 9.1Level: LLTClassification code 10027105Term: Medullary thyroid cancerEUCTR2006-001354-28-ITASTRAZENECA15
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-DKAstraZeneca AB80
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-DEAstraZeneca AB80
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-NLAstraZeneca AB80
进行中（未招募）
不适用
A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular diseaseEUCTR2007-004252-37-FRInnate Pharma